biote Corp. (NASDAQ:BTMD – Get Free Report) major shareholder Guines Llc bought 750,000 shares of biote stock in a transaction dated Thursday, March 13th. The shares were bought at an average cost of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the acquisition, the insider now owns 3,820,938 shares in the company, valued at $12,303,420.36. This represents a 24.42 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Guines Llc also recently made the following trade(s):
- On Monday, March 17th, Guines Llc acquired 100 shares of biote stock. The stock was acquired at an average cost of $3.74 per share, for a total transaction of $374.00.
biote Trading Up 1.8 %
biote stock opened at $4.07 on Wednesday. The company has a market capitalization of $221.15 million, a PE ratio of 15.65 and a beta of 1.07. biote Corp. has a 12 month low of $3.04 and a 12 month high of $8.44. The stock has a 50-day moving average price of $4.88 and a two-hundred day moving average price of $5.51.
Hedge Funds Weigh In On biote
Wall Street Analyst Weigh In
Separately, Craig Hallum reduced their price objective on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.
Check Out Our Latest Analysis on biote
biote Company Profile
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Recommended Stories
- Five stocks we like better than biote
- What is a Special Dividend?
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- 3 Must-Own Stocks to Build Wealth This Decade
- 3 Tickers Leading a Meme Stock Revival
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.